EFFICACY AND SAFETY OF EBRONUCIMAB, IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA AND MIXED HYPERLIPIDEMIA: RESULTS FROM A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE III CLINICAL STUDY

被引：0
|
作者：
Huo, Y. [1 ]
Zheng, B. [1 ]
Xia, Y. [2 ]
Wang, M. [2 ]
Li, B. [2 ]
Ni, X. [2 ]
Wang, G. [2 ]
Yu, B. [2 ]
机构：
[1] Peking Univ First Hosp, Cardiovasc, Beijing, Peoples R China
[2] Akeso Biopharma Inc, Clin Dept, Zhongshan, Peoples R China
来源：
ATHEROSCLEROSIS | 2023年 / 379卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P608
引用
收藏
页码：S198 / S199
页数：2
相关论文
共 50 条
  • [31] EFFICACY AND SAFETY OF QUETIAPINE FOR DELIRIUM IN ICU PATIENTS:A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY
    Devlin, John W.
    Roberts, Russel
    Fong, Jeffrey J.
    Skrobik, Yoanna
    Harvey, Johanne
    Riker, Richard
    Robbins, Tracey
    Hill, Nicholas
    Garpestad, Erik
    CRITICAL CARE MEDICINE, 2008, 36 (12) : A17 - A17
  • [32] Safety of efalizumab in patients with psoriatic arthritis: Results of a phase II, randomized, double-blind, placebo-controlled study
    Papp, K
    Mease, P
    Garovoy, M
    Zhang, D
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2004, 50 (03) : P156 - P156
  • [33] Efficacy and safety of nemolizumab and topical corticosteroids for prurigo nodularis: results from a randomized double-blind placebo-controlled phase II/III clinical study in patients aged ≥ 13 years
    Yokozeki, Hiroo
    Murota, Hiroyuki
    Matsumura, Takayo
    Komazaki, Hiroshi
    BRITISH JOURNAL OF DERMATOLOGY, 2024, 191 (02) : 200 - 208
  • [34] Efficacy and Safety of Abatacept Over 12 Months in Patients with Lupus Nephritis: Results From a Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase II/III Study
    Furie, Richard
    Nicholls, Kathy
    Cheng, Tien-Tsai
    Houssiau, Frederic
    Burgos-Vargas, Ruben
    Chen, Shun-Le
    Aranda, Richard
    Meadows-Shropshire, Stephanie
    Kinaszczuk, Michael
    Merrill, Joan T.
    ARTHRITIS AND RHEUMATISM, 2011, 63 (10): : S962 - S963
  • [35] Safety and Efficacy of Levamisole in Loiasis: A Randomized, Placebo-controlled, Double-blind Clinical Trial
    Campillo, Jeremy T.
    Bikita, Paul
    Hemilembolo, Marlhand
    Louya, Frederic
    Missamou, Francois
    Pion, Sebastien D. S.
    Boussinesq, Michel
    Chesnais, CedricB
    CLINICAL INFECTIOUS DISEASES, 2022, 75 (01) : 19 - 27
  • [36] The efficacy and safety of eperisone in patients with cervical spondylosis: Results of a randomized, double-blind, placebo-controlled trial
    Bose, K
    METHODS AND FINDINGS IN EXPERIMENTAL AND CLINICAL PHARMACOLOGY, 1999, 21 (03): : 209 - 213
  • [37] Prospective, double-blind, randomized, placebo-controlled phase III study evaluating efficacy and safety of octagam 10% in patients with dermatomyositis ("ProDERM Study")
    Aggarwal, Rohit
    Charles-Schoeman, Christina
    Schessl, Joachim
    Dimachkie, Mazen M.
    Beckmann, Irene
    Levine, Todd
    MEDICINE, 2021, 100 (01) : E23677
  • [38] SAFETY OF AMISELIMOD IN HEALTHY SUBJECTS: RESULTS FROM A PHASE 1 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY
    Hanauer, Stephen
    O'Reilly, Terry
    Lester, Robert
    Slatkin, Neal
    Lee, Jimin
    Franklin, Howard
    Bulawski, Angela
    Israel, Robert
    GASTROENTEROLOGY, 2021, 160 (03) : S1 - S2
  • [39] SAFETY OF AMISELIMOD IN HEALTHY SUBJECTS: RESULTS FROM A PHASE 1 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY
    Hanauer, Stephen
    O'Reilly, Terry
    Lester, Robert
    Slatkin, Neal
    Lee, Jimin
    Franklin, Howard
    Bulawski, Angela
    Israel, Robert
    INFLAMMATORY BOWEL DISEASES, 2021, 27 : S1 - S1
  • [40] Safety and efficacy of ataluren in nmDMD patients from Study 041, a phase 3, randomized, double-blind, placebo-controlled trial
    McDonald, C.
    Wu, S.
    Gulati, S.
    Komaki, H.
    Ruiz-Garcia, M.
    Kostera-Pruszczyk, A.
    Vlodavets, D.
    Chae, J.
    Jong, Y.
    Karachunski, P.
    Statland, J.
    Lorentzos, M.
    Penematsa, V
    Chou, C.
    Lin, M.
    Werner, C.
    Trifillis, P.
    Gordon, G.
    Klein, M.
    NEUROMUSCULAR DISORDERS, 2022, 32
12345